GVEZX Performance — Value Equity Fund, Investor Class
Data updated: 2026-09-18
GVEZX returned +9.14% year to date and +19.53% over one year to Jun 2026. Annualised returns are +15.07% over 3 years and +9.79% over 5 years. The fund trailed its US Large Value category average: $100 invested three years ago grew to $152, against $158 for the category, and to $120 over one year, against $121. Volatility over the past three years was 12.07% a year. In the 12 months to Jun 2026 the fund lost a net $160.2M, and assets reached $878.42M.
GVEZX Growth of $100
What $100 invested in Value Equity Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Large Value category average over the same months.
| Period | GVEZX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $120 | $121 |
| 3 years (Jul 2023 – Jun 2026) | $152 | $158 |
| 5 years (Jul 2021 – Jun 2026) | $160 | $165 |
| Since data start (Jul 2019 – Jun 2026) | $210 | $223 |
GVEZX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +9.14% |
| 1 year | +19.53% |
| 3 years (annualised) | +15.07% |
| 5 years (annualised) | +9.79% |
GVEZX Annual Returns
Calendar-year total returns of Value Equity Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +9.14% |
| 2025 | +13.88% |
| 2024 | +15.84% |
| 2023 | +10.55% |
| 2022 | −6.17% |
| 2021 | +24.28% |
| 2020 | +3.92% |
| 2019 (Jul–Dec) | +9.00% |
GVEZX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.0% | +2.7% | −6.2% | +7.5% | +1.4% | +0.8% | — | — | — | — | — | — |
| 2025 | +4.2% | +0.2% | −3.6% | −4.2% | +3.3% | +4.4% | +1.0% | +3.6% | +1.3% | +0.8% | +1.8% | +0.7% |
| 2024 | +1.0% | +2.8% | +4.9% | −4.0% | +3.1% | −1.0% | +5.0% | +2.6% | +1.8% | −0.6% | +5.6% | −5.5% |
| 2023 | +4.7% | −3.4% | −1.2% | +1.7% | −3.4% | +6.3% | +3.2% | −2.6% | −3.5% | −2.7% | +7.1% | +4.8% |
| 2022 | −2.2% | −0.9% | +2.4% | −5.9% | +2.4% | −8.1% | +5.8% | −2.4% | −8.3% | +10.5% | +5.5% | −3.3% |
| 2021 | −0.9% | +5.5% | +6.3% | +4.0% | +2.0% | −1.2% | +0.4% | +1.9% | −3.9% | +5.3% | −3.3% | +6.7% |
| 2020 | −3.2% | −10.0% | −16.3% | +10.9% | +4.7% | −0.1% | +4.0% | +4.0% | −1.9% | −1.7% | +13.3% | +3.9% |
| 2019 | — | — | — | — | — | — | +1.1% | −2.2% | +3.4% | +1.1% | +3.3% | +2.1% |
GVEZX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 12.07%
- 3-year Sharpe ratio: 0.88 (vs 4.5% risk-free rate)
- Best month: +7.54% (Apr 2026)
- Worst month: −6.20% (Mar 2026)
GVEZX Fund Flows
Monthly money in and out of Value Equity Fund, from SEC Form N-PORT.
- 12-month net flow: −$160.2M
- 12-month gross sales (incl. reinvestments): $267.4M
- Sales ÷ redemptions: 0.63×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $41.8M | $17.7M | $24.2M |
| May 2026 | $6.9M | $8.1M | −$1.2M |
| Apr 2026 | $11.8M | $7.3M | $4.5M |
| Mar 2026 | $17.9M | $273.9M | −$256.0M |
| Feb 2026 | $9.7M | $18.3M | −$8.6M |
| Jan 2026 | $7.5M | $26.7M | −$19.2M |
| Dec 2025 | $117.7M | $18.9M | $98.8M |
| Nov 2025 | $6.0M | $12.8M | −$6.8M |
| Oct 2025 | $7.5M | $9.5M | −$2.0M |
| Sep 2025 | $7.6M | $9.9M | −$2.3M |
| Aug 2025 | $17.9M | $10.9M | $7.1M |
| Jul 2025 | $15.0M | $13.6M | $1.4M |
GVEZX Assets Under Management
Net assets of Value Equity Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $878.42M |
| 2026-03-31 | $804.16M |
| 2025-12-31 | $1.09B |
| 2025-09-30 | $1.08B |
| 2025-06-30 | $1.01B |
| 2025-03-31 | $972.30M |
| 2024-12-31 | $1.07B |
| 2024-09-30 | $1.09B |
| 2024-06-28 | $1.04B |
| 2024-03-28 | $1.07B |
| 2023-12-29 | $981.81M |
| 2023-09-29 | $905.22M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.